For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo
Modern Restaurant Management [MRM]
*Correspondence: Jixin Zhong, [email protected]
doi: 10.3389/fmed.2026.1752341 Received 23 November 2025 Revised 04 April 2026 Accepted 10 April 2026 Published 29 April 2026 Volume 13 - 2026 Edited by Wei Liu, Huazhong University of Science and Technology, China Reviewed by Jheng-Yan Wu, Chi Mei Medical Center, Taiwan Jennifer Teske, University of Arizona, United States Updates Copyright 2026 Fang, Zhu, Rao and Liu
WL Weight loss A recent network meta-analysis including 27 RCTs and 15,584 participants evaluated efficacy and safety of seven GLP-1 RAs and polyagonists (GLP-1/GIP or GLP-1/GIP/Glucagon) for weight management in individuals with overweight or obesity
GLP-1s are distinct from previous classes of prescription weight loss drugs such as phentermine, as they target essential metabolic pathways
